Jefferson Bridge Capital LLC Buys Shares of 52,798 Harrow, Inc. $HROW

Key Points

• Jefferson Bridge Capital LLC bought a new stake of 52,798 shares of Harrow in Q4 valued at approximately $2.59 million, representing about 2.6% of its portfolio and roughly 0.14% ownership of Harrow.
• Analysts have a consensus rating of Moderate Buy on HROW with a consensus price target of $69.86 (breakdown: 8 Buys, 2 Holds, 1 Sell).
• Harrow has a market capitalization of $1.32 billion, opened at $35.43 and trades in a 52‑week range of $20.85–$54.85, while showing a negative P/E of -208.4 and a debt‑to‑equity ratio of 4.67.

Jefferson Bridge Capital LLC bought a new stake in Harrow, Inc. (NASDAQ:HROW - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 52,798 shares of the company's stock, valued at approximately $2,587,000. Harrow makes up about 2.6% of Jefferson Bridge Capital LLC's portfolio, making the stock its 14th largest holding. Jefferson Bridge Capital LLC owned approximately 0.14% of Harrow as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Raymond James Financial Inc. acquired a new stake in shares of Harrow during the second quarter worth $48,000. State of Alaska Department of Revenue acquired a new stake in shares of Harrow during the third quarter worth $83,000. Tower Research Capital LLC TRC lifted its stake in shares of Harrow by 345.0% during the second quarter. Tower Research Capital LLC TRC now owns 3,373 shares of the company's stock worth $103,000 after buying an additional 2,615 shares during the period. Larson Financial Group LLC lifted its stake in shares of Harrow by 848.2% during the third quarter. Larson Financial Group LLC now owns 2,162 shares of the company's stock worth $104,000 after buying an additional 1,934 shares during the period. Finally, Strs Ohio acquired a new stake in shares of Harrow during the first quarter worth $149,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Harrow Stock Up 0.9%

HROW opened at $35.43 on Wednesday. Harrow, Inc. has a fifty-two week low of $20.85 and a fifty-two week high of $54.85. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The company has a fifty day moving average of $41.75 and a two-hundred day moving average of $43.05. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -208.40 and a beta of 0.31.

Analysts Set New Price Targets

Several equities research analysts have recently commented on HROW shares. HC Wainwright reiterated a "buy" rating and set a $70.00 price objective on shares of Harrow in a research note on Thursday, March 19th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Harrow in a research note on Thursday, January 22nd. BTIG Research reiterated a "buy" rating and set a $63.00 price objective on shares of Harrow in a research note on Wednesday, March 18th. Nomura downgraded shares of Harrow to a "neutral" rating in a research note on Wednesday, March 18th. Finally, William Blair reiterated an "outperform" rating on shares of Harrow in a research note on Tuesday, March 3rd. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $69.86.

About Harrow

Harrow Health, Inc NASDAQ: HROW is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.